Meanwhile, our results indicated that the targeted inhibitor of IL-6 may augment the efficacy of anti-PD-L1 in NSCLC, paving the path for the utilization of IL-6 as a therapeutic target for cancer treatment. Here, CD274 is linked to cancer.